Differential regulation of cardiac excitation-contraction coupling by cAMP phosphodiesterase subtypes

Cardiovascular Research

Volumn 100, Issue 2, 2013, Pages 336-346

  Mika, Delphine ^a,b   Bobin, Pierre ^a,b   Pomérance, Martine ^a,b   Lechêne, Patrick ^a,b   Westenbroek, Ruth E ^c   Catterall, William A ^c   Vandecasteele, Grégoire ^a,b   Leroy, Jérôme ^a,b   Fischmeister, Rodolphe ^a,b  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cAMP; Excitation contraction coupling; Phosphodiesterase; Protein phosphorylation

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM ION; CYCLIC AMP PHOSPHODIESTERASE; MYOSIN BINDING PROTEIN C; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHOLAMBAN; RYANODINE RECEPTOR; SPLEEN EXONUCLEASE; TROPONIN I;

ANIMAL EXPERIMENT; ARTICLE; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; EXCITATION CONTRACTION COUPLING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; SARCOMERE; SARCOMERE LENGTH; WESTERN BLOTTING;

CAMP; EXCITATION-CONTRACTION COUPLING; PHOSPHODIESTERASE; PROTEIN PHOSPHORYLATION;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; CALCIUM; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; EXCITATION CONTRACTION COUPLING; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; RATS; RATS, WISTAR;

EID: 84886034011     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt193     Document Type: Article

References (59)

1. Bers DM. Calcium cycling and signaling in cardiac myocytes. Ann Rev Physiol 2008;70: 23-49.
2. Conti M, Beavo JA. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Ann Rev Biochem 2007;76: 481-511.
3. Patrucco E, Albergine MS, Santana LF, Beavo JA. Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes. J Mol Cell Cardiol 2010;49: 330-333.
4. Soderling SH, Bayuga SJ, Beavo JA. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998;273:15553-15558.
5. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 1998;273: 15559-15564.
6. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006;109:366-398.
7. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: from molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520.
8. Méry P-F, Pavoine C, Pecker F, Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol 1995;48:121-130.
9. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004;47:1081-1092.
10. Rochais F, Vandecasteele G, Lefebvre F, Lugnier C, Lum H, Mazet J-L et al. Negative feedback exerted by PKA and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes. An in vivo study using adenovirus-mediated expression of CNG channels. J Biol Chem 2004;279:52095- 52105.
11. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 2004;95:65-75.
12. scoupled receptors in adult rat ventricular myocytes. Circ Res 2006;98:1081-1088.
13. 2-adrenergic receptor-mediated signaling. Circ Res 2006;99:1084-1091.
14. 2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circ Res 2008;102: 1091-1100.
15. Fischmeister R, Castro LRV, Abi-Gerges A, Rochais F, Jurevičius J, Leroy J et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 2006;99:816-828.
16. Scott JD, Santana LF. A-kinase anchoring proteins: getting to the heart of the matter. Circulation 2010;121:1264-1271.
17. 2+ leak: a novel therapeutic target in heart failure. Circulation 2005;111:3342-3346.
18. Kerfant BG, Zhao D, Lorenzen-Schmidt I, Wilson LS, Cai S, Chen SR et al. PI3KY is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res 2007;101:400-408.
19. 2+ current in single heart cells. Nature 1986;323:273-275.
20. Malecot C, Bers DM, Katzung BG. Biphasic contractions induced by milrinone at low temperature in ferret ventricular muscle: role of the sarcoplasmic reticulum and transmembrane calcium influx. Circ Res 1986;59:151-162.
21. Rivet-Bastide M, Vandecasteele G, Hatem S, Verde I, Benardeau A, Mercadier JJ et al. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest 1997;99:2710-2718.
22. Kajimoto K, Hagiwara N, Kasanuki H, Hosoda S. Contribution of phosphodiesterase isozymes to the regulation of the L-type calcium current in human cardiac myocytes. Br J Pharmacol 1997;121:1549-1556.
23. 2+ current in rat ventricular myocytes. Br J Pharmacol 1999;127:65-74.
24. 2+ channel current in human atrial myocytes. J Physiol 2001;533:329-340.
25. 2+ current and protects against ventricular arrhythmias. J Clin Invest 2011;121:2651-2661.
26. 2+ uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol 2000;279:H1898-H1905.
27. 2+ release. J Pharmacol Exp Ther 2004;310:761-773.
28. Beca S, Ahmad F, Shen W, Liu J, Makary S, Polidovitch N et al. PDE3Aregulates basal myocardial contractility through interacting with SERCA2a-signaling complexes in mouse heart. Circ Res 2013;112:289-297.
29. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA. Isolation and characterization of bovine cardiacmuscle cGMP-inhibited phosphodiesterase: a receptor for newcardiotonic drugs. Mol Pharmacol 1986;29:506-514.
30. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMPspecific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 1987;61:539-547.
31. Komas N, Lugnier C, Le Bec A, Serradeil-Le Gal C, Barthelemy G, Stoclet JC. Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues. J Cardiovasc Pharmacol 1989;14:213-220.
32. Osadchii OE. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc Drugs Ther 2007;21:171-194.
33. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR et al. Compartmentalized phosphodiesterase-2 activity blunts β-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 2006;98:226-234.
34. Muller B, Lugnier C, Stoclet JC. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction. J Cardiovasc Pharmacol 1990;16: 796-803.
35. Katano Y, Endoh M. CyclicAMP metabolism in intact rat ventricular cardiac myocytes-interaction of carbachol with isoproterenol and 3-isobutyl-1- methylxanthine. Mol Cell Biochem 1993;119:195-201.
36. Katano Y, Endoh M. Differential effects of Ro 20-1724 and isobutylmethylxanthine on the basal force of contraction and beta-adrenoceptor-mediated response in the rat ventricular myocardium. Biochem Biophys Res Commun 1990;167:123-129.
37. 2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart. Br J Pharmacol 2009;156:62-83.
38. Herzer WA, Thomas NJ, Carcillo JA, Tofovic SP, Jackson EK. Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines. J Cardiovasc Pharmacol 1998;32:769-776.
39. Juan-Fita MJ, Vargas ML, Hernandez J. Comparative actions of diazepam and other phosphodiesterase inhibitors on the effects of noradrenaline in rat myocardium. Pharmacol Toxicol 2003;93:23-28.
40. Beavo JA, Francis SH, Houslay MD. Cyclic nucleotide phosphodiesterases in health and disease. Boca Raton, Florida, USA: CRC Press, Taylor & Francis Group 2007; pp. 1-713.
41. Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T et al. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 1979;211:26-30.
42. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000;59:347-356.
43. Rose RJ, Liu H, Palmer D, Maurice DH. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J Pharmacol 1997;122: 233-240.
44. Rich TC, Tse TE, Rohan JG, Schaack J, Karpen JW. In vivo assessment of local phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP sensors. J Gen Physiol 2001;118:63-77.
45. v1.2 channels via a leucine zipper interaction with A kinase-anchoring protein 15. Proc Natl Acad Sci USA 2003;100: 13093-13098.
46. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinasedependent and -independent effects. Cell 2004;118:375-387.
47. Grimm M, Brown JH. β-Adrenergic receptor signaling in the heart: role of CaMKII. J Mol Cell Cardiol 2010;48:322-330.
48. Trafford AW, Diaz ME, Eisner DA. Stimulation of Ca-induced Ca release only transiently increases the systolic Ca transient: measurements of Ca fluxes and sarcoplasmic reticulum Ca. Cardiovasc Res 1998;37:710-717.
49. 2+ current trigger. J Physiol 2004; 556:463-480.
50. Cazorla O, Lucas A, Poirier F, Lacampagne A, Lezoualc'h F. The cAMP binding protein Epac regulates cardiac myofilament function. Proc Natl Acad USA 2009;106:14144-14149.
51. Lugnier C, Muller B, Lebec A, Beaudry C, Rousseau E. Characterization of indolidansensitive and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther 1993;265:1142-1151.
52. Movsesian MA. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: Shifting the focus from inotropy to cyclic adenosine monophosphate. J Am Coll Cardiol 1999;34:318-324.
53. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 2001;66:241-277.
54. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG et al. The two GAFdomains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci USA 2002;99:13260-13265.
55. Stangherlin A, Gesellchen F, Zoccarato A, Terrin A, Fields LA, Berrera M et al. cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ Res 2011;108:929-939.
56. Konstam MA, Cody RJ. Short-term use of intravenous milrinone for heart failure. Am J Cardiol 1995;75:822-826.
57. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-1475.
58. Richter W, Xie M, Scheitrum C, Krall J, Movsesian MA, Conti M. Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol 2011;106:249-262.
59. Mika D, Leroy J, Vandecasteele G, Fischmeister R. PDEs create local domains of cAMP signaling. J Mol Cell Cardiol 2012;52:323-329.